HIF1A and familial pancreatic carcinoma: Therapeutic strategies targeting the HIF-1α/TGF-β1 axis hold significant promise in pancreatic cancer, but efficacy and safety require optimization through refined dosing regimens, selective inhibitors, and multi-target combinations.